+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Viral Therapies Market by Type, Application, and Mechanism of Action: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5125453
  • Report
  • May 2020
  • Region: Global
  • 238 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bristol-Myers-Squibb
  • F. Hoffmann-La Roche Ltd.
The global anti-viral therapies market was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026. Antiviral drugs belong to the class of medicines, which are used for treating viral infections, such as HIV, herpes, hepatitis, and influenza. These drugs are generally administered in the form of vaccines. In addition, most of these drugs are used for specific viral infections, while a few (broad-spectrum antiviral drugs) are effective against a wide range of viruses.



The global antiviral therapies market is majorly driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy along with pipeline products, are expected to fuel the market growth. However, high cost involved in the treatment and a rise in demand for alternative medicines such as naturopathy and homeopathy are likely to restrain the market growth. On the contrary, development and approvals of combination therapies and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to provide numerous opportunities for the market growth during the forecast period.

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. On the basis of type, it is classified into generic drugs and branded drugs. By mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global clinical nutrition market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

BY Application
  • HIV
  • Hepatitis
  • Herpes Virus
  • Influenza
  • Other Applications

BY Type
  • Generic Drugs
  • Branded Drugs

BY Mechanism of Action
  • Nucleotide Polymerase Inhibitor
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, GlaxoSmithKline
  • Bristol-Myers-Squibb
  • Abbott Laboratories
  • AstraZeneca plc
  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Johnson & Johnson
  • Merck & Co., Inc
Frequently Asked Questions about the Global Anti-Viral Therapies Market

What is the estimated value of the Global Anti-Viral Therapies Market?

The Global Anti-Viral Therapies Market was estimated to be valued at $38316.5 million in 2018.

What is the growth rate of the Global Anti-Viral Therapies Market?

The growth rate of the Global Anti-Viral Therapies Market is 2.4%, with an estimated value of $46213.4 million by 2026.

What is the forecasted size of the Global Anti-Viral Therapies Market?

The Global Anti-Viral Therapies Market is estimated to be worth $46213.4 million by 2026.

Who are the key companies in the Global Anti-Viral Therapies Market?

Key companies in the Global Anti-Viral Therapies Market include F. Hoffmann, La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol, Myers, Squibb, Abbott Laboratories and AbbVie Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bristol-Myers-Squibb
  • F. Hoffmann-La Roche Ltd.

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. CXO Perspective
Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Surge in Global Burden of Viral Infection
3.3.1.2. Stronger Pipeline of Anti-Viral Drugs
3.3.2. Restraints
3.3.2.1. Higher Cost of Treatment
3.3.3. Opportunities
3.3.3.1. Increase in Number of Product Approvals for Combination Therapy
Chapter 4: Anti-Viral Therapies Market, by Application
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Hiv
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Hepatitis
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Herpes Virus
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country
4.5. Influenza
4.5.1. Key Market Trends, Growth Factors, and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis, by Country
4.6. Other Applications
4.6.1. Key Market Trends, Growth Factors, and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Analysis, by Country
Chapter 5: Anti-Viral Therapies Market, by Type
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Generic Drugs
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Analysis, by Country
5.3. Branded Drugs
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
Chapter 6: Anti-Viral Therapies Market, by Mechanism of Action
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Nucleotide Polymerase Inhibitor
6.2.1. Market Size and Forecast, by Region
6.2.2. Market Analysis, by Country
6.3. Reverse Transcriptase Inhibitors
6.3.1. Market Size and Forecast, by Region
6.3.2. Market Analysis, by Country
6.4. Protease Inhibitors
6.4.1. Market Size and Forecast, by Region
6.4.2. Market Analysis, by Country
6.5. Others
6.5.1. Market Size and Forecast, by Region
6.5.2. Market Analysis, by Country
Chapter 7: Global Anti-Viral Therapies Market, by Region
7.1. Overview
7.1.1. Market Size and Forecast
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, by Type
7.2.3. Market Size and Forecast, by Mechanism of Action
7.2.4. Market Size and Forecast, by Application
7.2.5. Market Size and Forecast, by Country
7.2.5.1. U. S. Market Size and Forecast, by Type
7.2.5.2. U. S. Market Size and Forecast, by Mechanism of Action
7.2.5.3. U. S. Market Size and Forecast, by Application
7.2.5.4. Canada Market Size and Forecast, by Type
7.2.5.5. Canada Market Size and Forecast, by Mechanism of Action
7.2.5.6. Canada Market Size and Forecast, by Application
7.2.5.7. Mexico Market Size and Forecast, by Type
7.2.5.8. Mexico Market Size and Forecast, by Mechanism of Action
7.2.5.9. Mexico Market Size and Forecast, by Application
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, by Type
7.3.3. Market Size and Forecast, by Mechanism of Action
7.3.4. Market Size and Forecast, by Application
7.3.5. Market Size and Forecast, by Country
7.3.5.1. Germany Market Size and Forecast, by Type
7.3.5.2. Germany Market Size and Forecast, by Mechanism of Action
7.3.5.3. Germany Market Size and Forecast, by Application
7.3.5.4. France Market Size and Forecast, by Type
7.3.5.5. France Market Size and Forecast, by Mechanism of Action
7.3.5.6. France Market Size and Forecast, by Application
7.3.5.7. UK Market Size and Forecast, by Type
7.3.5.8. UK Market Size and Forecast, by Mechanism of Action
7.3.5.9. UK Market Size and Forecast, by Application
7.3.5.10. Italy Market Size and Forecast, by Type
7.3.5.11. Italy Market Size and Forecast, by Mechanism of Action
7.3.5.12. Italy Market Size and Forecast, by Application
7.3.5.13. Spain Market Size and Forecast, by Type
7.3.5.14. Spain Market Size and Forecast, by Mechanism of Action
7.3.5.15. Spain Market Size and Forecast, by Application
7.3.5.16. Rest of Europe Market Size and Forecast, by Type
7.3.5.17. Rest of Europe Market Size and Forecast, by Mechanism of Action
7.3.5.18. Rest of Europe Market Size and Forecast, by Application
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, by Type
7.4.3. Market Size and Forecast, by Mechanism of Action
7.4.4. Market Size and Forecast, by Application
7.4.5. Market Size and Forecast, by Country
7.4.5.1. Japan Market Size and Forecast, by Type
7.4.5.2. Japan Market Size and Forecast, by Mechanism of Action
7.4.5.3. Japan Market Size and Forecast, by Application
7.4.5.4. China Market Size and Forecast, by Type
7.4.5.5. China Market Size and Forecast, by Mechanism of Action
7.4.5.6. China Market Size and Forecast, by Application
7.4.5.7. India Market Size and Forecast, by Type
7.4.5.8. India Market Size and Forecast, by Mechanism of Action
7.4.5.9. India Market Size and Forecast, by Application
7.4.5.10. Australia Market Size and Forecast, by Type
7.4.5.11. Australia Market Size and Forecast, by Mechanism of Action
7.4.5.12. Australia Market Size and Forecast, by Application
7.4.5.13. South Korea Market Size and Forecast, by Type
7.4.5.14. South Korea Market Size and Forecast, by Mechanism of Action
7.4.5.15. South Korea Market Size and Forecast, by Application
7.4.5.16. Rest of Asia-Pacific Market Size and Forecast, by Type
7.4.5.17. Rest of Asia-Pacific Market Size and Forecast, by Mechanism of Action
7.4.5.18. Rest of Asia-Pacific Market Size and Forecast, by Application
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, by Type
7.5.3. Market Size and Forecast, by Mechanism of Action
7.5.4. Market Size and Forecast, by Application
7.5.5. Market Size and Forecast, by Country
7.5.5.1. Brazil Market Size and Forecast, by Type
7.5.5.2. Brazil Market Size and Forecast, by Mechanism of Action
7.5.5.3. Brazil Market Size and Forecast, by Application
7.5.5.4. Saudi Market Size and Forecast, by Type
7.5.5.5. Saudi Market Size and Forecast, by Mechanism of Action
7.5.5.6. Saudi Market Size and Forecast, by Application
7.5.5.7. South Africa Market Size and Forecast, by Type
7.5.5.8. South Africa Market Size and Forecast, by Mechanism of Action
7.5.5.9. South Africa Market Size and Forecast, by Application
7.5.5.10. Rest of LAMEA Market Size and Forecast, by Type
7.5.5.11. Rest of LAMEA Market Size and Forecast, by Mechanism of Action
7.5.5.12. Rest of LAMEA Market Size and Forecast, by Application
Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Abbvie Inc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Business Performance
8.2.5. Key Strategic Moves and Developments
8.3. Bristol Myers Squibb Company
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. F. Hoffmann-La Roche Ltd.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves and Developments
8.5. Johnson & Johnson
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Business Performance
8.6. Merck & Co. Inc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Business Performance
8.6.5. Key Strategic Moves and Developments
8.7. Gilead Sciences, Inc.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves and Developments
8.8. GlaxoSmithKline plc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves and Developments
8.9. Astrazeneca plc
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.9.6. Key Strategic Moves and Developments
8.10. Aurobindo Pharma Limited
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bristol-Myers-Squibb
  • F. Hoffmann-La Roche Ltd.
According to the report titled, 'Anti-viral. Therapies Market by Application, Type, and Mechanism of Action: Opportunity Analysis and Industry Forecast, 2019-2026' the global anti-viral therapies market size was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026. Antiviral therapies make use of drugs that inhibit the development of the virus causing infection.. These drugs do not kill the target pathogen directly.. These therapies are mostly particular against viral infections and do not cause side effects in the host’s body. Anti-viral therapies are widely used in treating HIV, herpes, hepatitis, influenza and other viral infections such as chicken pox and papilloma.

The factors that drive the growth of the market include rise in prevalence of viral infections globally and presence of robust product pipeline with several pharmaceutical giants. Conversely, higher cost for treating these infections and shift in preference of the patients toward homeopathy and naturopathy are some of the key issues expected to hinder the antiviral therapies market growth. On the contrary, R&D for developing combination therapies to effectively eradicate the infections is anticipated to provide lucrative opportunities for the growth of the anti-viral therapies market during the forecast period.

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. HIV segment was the largest revenue contributor to the anti-viral therapies market in 2018 and is expected to continue this trend during the forecast period, owing to increase in incidences of HIV globally. For instance, as per the data published by UNAIDS, in 2017, around 37 million of the global population is living with HIV. The prevalence of HIV among adults was estimated to be 0.8%. Moreover, an increase in consumption of HIV anti-viral drugs for combating infection is major driving factor for the growth of the anti-viral therapies market for HIV segment. On the basis of type, it is classified into generic drugs and branded drugs. The branded drugs segment is a major revenue contributor to the anti-viral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to availability of large number of branded drugs for treating various viral infections. On the basis of mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. The nucleotide polymerase inhibitor segment is considered as the most lucrative segment in the anti-viral therapies market, owing to its increasing usage in Hepatitis C infection and are considered to be the first-line treatment for any viral infection. This increase in the usage of nucleotide polymerase inhibitor for treating viral infection is expected to boost the growth of the market during the forecast period. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the global antiviral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to rise inincidences of infectious diseases across the region. Favorable government initiatives undertaken by the U.S. government to combat the prevalence and occurrence of infectious diseases across the North American region are expected to provide ample opportunities for the growth of the anti-viral therapies market in the coming years. Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to presence of several generic pharmaceutical players and increase in investment for drug development in South Asian countries.

The report provides a comprehensive analysis of the key players operating in the global anti-viral therapies market, which include F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc, AbbVie Inc., Aurobindo Pharma Limited, Johnson & Johnson, and Merck & Co., Inc. The other players in the value chain (companies not included in the report) include Schering-Plough Corporation, Cipla, and Dr Reddy’s.

Key Findings of the Study:

Nucleotide polymerase inhibitor segment occupied 38.44% share of the global anti-viral therapies market in 2018.
By application, HIV segment is anticipated to grow with the highest CAGR throughout the forecast period.
By type, the generic drugs segment accounted for 46.8% share of the market in 2018.
Asia-Pacific is anticipated to grow at the 2.8% during the analysis period.
Note: Product cover images may vary from those shown
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • GlaxoSmithKline
  • Bristol-Myers-Squibb
  • Abbott Laboratories
  • AstraZeneca plc
  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Johnson & Johnson
  • Merck & Co. Inc
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...